FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus
On May 22, 2026, Gilead Sciences announced announced that the U.S. Food and Drug Administration (FDA) has granted…